Cone Biopsy Of Cervix — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cone biopsy of the cervix, also called cervical conisation, is a surgical procedure in which a cone-shaped section of tissue is removed from the cervix (the lower part of the uterus that opens into the vagina) for diagnostic and therapeutic purposes. The term describes the shape of the tissue removed — a cone with its base at the outer surface of the cervix (ectocervix) and its apex directed towards the endocervical canal.

Conisation is most commonly performed to treat cervical intraepithelial neoplasia (CIN) — precancerous changes in the cervical epithelium that, if untreated, can progress to invasive cervical cancer over years to decades. It is also performed to fully characterise and treat early-stage microinvasive cervical cancer (Stage IA1) and to obtain a diagnostic tissue specimen when colposcopy-directed biopsies have shown CIN2+ but have not fully assessed the extent of the lesion or the endocervical margin.

Two main techniques are used in contemporary gynaecological practice: Large Loop Excision of the Transformation Zone (LLETZ), also known as LEEP (Loop Electrosurgical Excision Procedure) in North America, which uses a wire loop with diathermy current to excise the transformation zone in an outpatient setting under local anaesthesia; and cold knife conisation (CKC), performed in an operating theatre under general or regional anaesthesia, using a scalpel to cut a precise cone of cervical tissue. The choice between techniques is guided by the extent and location of the lesion, the colposcopic findings, and the clinical situation.

Cervical intraepithelial neoplasia (CIN) is the primary indication for cone biopsy. CIN is classified histologically as CIN1 (mild dysplasia — often regresses spontaneously), CIN2 (moderate dysplasia — treatment recommended as regression is less reliable), and CIN3 (severe dysplasia / carcinoma in situ — definitive treatment required). The transformation zone (TZ) where the stratified squamous epithelium of the ectocervix meets the columnar epithelium of the endocervix is the site where virtually all cervical HPV-related precancerous changes occur.

Cone biopsy is specifically indicated for: CIN2 or CIN3 confirmed on colposcopy-directed biopsy; CIN of any grade with an unsatisfactory colposcopy (the transformation zone is not fully visible); glandular abnormalities including adenocarcinoma in situ (AIS) of the cervix — an endocervical precancer requiring cold knife cone biopsy for complete excision and assessment of margins; and microinvasive cervical cancer (FIGO Stage IA1, ≤3mm invasion depth) as potentially curative treatment in patients wishing to preserve fertility. It is also used to investigate a discordant result between cytology (smear), HPV testing, and colposcopy-directed biopsy.

Women with histologically confirmed CIN2 or CIN3 on colposcopy-directed biopsy are candidates for LLETZ treatment. CIN1 may be offered LLETZ if it has persisted for over 2 years or if the patient is HIV-positive or immunosuppressed. Cold knife conisation is specifically indicated when adenocarcinoma in situ (AIS) is diagnosed on biopsy, when the lesion extends into the endocervical canal beyond the reach of LLETZ, when the transformation zone is type 3 (fully endocervical) and not accessible to LLETZ, and when precise histological assessment of margins is required for staging purposes.

Pregnancy requires individualised management: LLETZ during pregnancy carries risks of preterm labour and bleeding and is generally deferred until the third trimester or after delivery if CIN2–3 is confirmed, with the exception of a suspected microinvasive or invasive cancer requiring immediate assessment. Contraindications include active cervicitis or lower genital tract infection (delay treatment until treated), coagulopathy or anticoagulation requiring perioperative management, and cervical length <25mm in women at high risk of preterm birth (where the additional risk of cervical shortening must be carefully considered).

LLETZ (Large Loop Excision of the Transformation Zone / LEEP) is the standard outpatient treatment for CIN2 and CIN3. Performed under local cervical anaesthesia (2% lidocaine with adrenaline), a stainless steel wire loop with a thin wall is passed through the transformation zone under colposcopic guidance with diathermy current, simultaneously cutting the tissue and coagulating blood vessels. The resulting cone specimen is sent for histological analysis. The endocervical margin status is critical: a positive endocervical margin (CIN extending to the cut edge) indicates a risk of residual disease and may require further treatment or closer surveillance.

Cold knife conisation (CKC) under general anaesthesia uses a scalpel to excise a precisely shaped cone under direct colposcopic visualisation. The advantage of CKC over LLETZ is that the specimen has a precise, undistorted margin that allows accurate histological assessment — the electrical current of LLETZ can cause thermal artefact at the margins, potentially obscuring microinvasive cancer or the true margin status of AIS. CKC achieves larger specimens with better endocervical margins and is the preferred technique for AIS and microinvasive cancer assessment. The specimen is orientated and submitted to pathology in a systematic fashion for comprehensive histological mapping.

Individualised treatment planning is essential to achieve optimal outcomes. Factors including patient age, overall health status, concurrent medications, and personal goals all influence the selection and sequencing of treatment approaches. A specialist consultation — with review of relevant investigations and prior treatment history — is the appropriate first step before any therapeutic intervention is initiated. Patients are encouraged to seek a second opinion for complex or elective procedures to ensure they understand all available options and their respective risks, benefits, and costs.

LLETZ treatment of CIN2–3 achieves clearance of precancerous disease in approximately 85–95% of cases at the first treatment. The treatment success rate is defined by clear histological excision margins and negative HPV testing 6 months post-treatment. Risk of residual or recurrent CIN after a single LLETZ with clear margins is approximately 5–8%; this rises to 20–30% if the endocervical margin is involved with CIN3.

Cone biopsy effectively prevents the progression of untreated CIN2–3 to invasive cervical cancer, providing the majority of women with definitive treatment in a single outpatient procedure of 15–20 minutes. Cold knife conisation achieves complete excision of AIS in approximately 80–90% of cases when negative margins are obtained. For Stage IA1 microinvasive cervical cancer in women wishing fertility preservation, CKC with clear margins can be considered curative treatment with surveillance, achieving disease-free survival comparable to hysterectomy in carefully selected patients at specialist centres.

Immediate complications of LLETZ include bleeding during or after the procedure in approximately 2–5% of cases — usually managed with adrenaline injection or thermal coagulation at the time, or with secondary haemostasis treatment for delayed bleeding (which occurs in up to 2% of cases 1–3 weeks post-procedure). Cervical infection (presenting with offensive discharge and pelvic pain) affects 2–5% of cases and requires antibiotic treatment.

The most clinically significant long-term risk of cone biopsy is cervical shortening and cervical incompetence, which is associated with an increased risk of preterm birth in subsequent pregnancies. A meta-analysis of multiple studies demonstrates that LLETZ increases the risk of preterm delivery (before 37 weeks) by approximately 60–70% relative to untreated women. The risk is proportional to the amount of cervical tissue removed (depth of excision), and is higher after CKC than LLETZ. Women who have had cone biopsy and subsequently become pregnant should be referred to a high-risk obstetric unit for surveillance of cervical length and consideration of cervical cerclage (a stitch to support the cervix). Cervical stenosis (narrowing of the cervical canal) occurs in 1–2% of cone biopsies and may cause painful periods or difficulty with cervical access at future colposcopy.

After LLETZ, patients are advised to expect a watery or bloody discharge for 2–4 weeks while the cervix heals. Sexual intercourse, tampons, and swimming should be avoided for 4 weeks. Heavy lifting and strenuous exercise should be minimised for 2 weeks. Patients should attend the emergency gynaecology unit immediately for heavy bleeding (soaking more than a sanitary pad per hour), offensive discharge with fever, or severe pelvic pain.

Post-treatment surveillance follows the histological result and margin status. For LLETZ with clear margins and CIN2–3, follow-up is with cervical smear (or combined smear and high-risk HPV test) at 6 months. If the smear and HPV test are negative at 6 months, the patient is discharged to 3–5 yearly routine screening. If the HPV test remains positive or margins were involved, surveillance is continued at 6–12 monthly intervals. For AIS, 6-monthly smear and HPV testing is continued for 5 years even with negative margins. Persistent HPV positivity or abnormal smear on follow-up requires repeat colposcopy.

LLETZ treatment in the United States costs USD 1,500–4,000 including the colposcopy, procedure, and pathology. Cold knife conisation under general anaesthesia costs USD 3,000–7,000. In the UK, both LLETZ and CKC are available on the NHS free at the point of care through colposcopy clinics, with no out-of-pocket cost. Private LLETZ in the UK costs GBP 800–1,500.

Medical tourism for cone biopsy of the cervix at gynaecological clinics in India (Mumbai, Delhi, Bangalore), Thailand (Bangkok), or Turkey (Istanbul) costs USD 200–700 for LLETZ and USD 500–1,500 for cold knife conisation — representing savings of 70–80% compared to US private rates. Women seeking cone biopsy abroad should ensure the colposcopy is performed by a trained colposcopist, that the specimen is appropriately assessed by a gynaecological pathologist, and that follow-up cervical smear and HPV testing can be arranged in their home country.

For CIN1 in women who are HPV-positive, watchful waiting with 6–12 monthly repeat cervical cytology and HPV testing is appropriate for the first 1–2 years as the majority of CIN1 regresses spontaneously with clearance of the causative HPV type. Ablative treatments — including cryotherapy, cold coagulation (radical thermocoagulation), and laser ablation — destroy the transformation zone without creating a specimen for histology. They are appropriate for CIN2–3 when the entire transformation zone is visible colposcopically and there is no suspicion of invasive disease or glandular abnormality. LLETZ is generally preferred in resource-adequate settings as it provides histological confirmation of diagnosis and margin status.

Hysterectomy is considered for CIN3 or AIS in women who have completed their family, or for recurrent CIN after multiple excisions, but is an irreversible and disproportionate treatment for initial CIN management. HPV vaccination (Gardasil 9) protects against HPV types 16, 18, 31, 33, 45, 52, and 58 — responsible for approximately 90% of cervical cancers — and when given before HPV exposure prevents the vast majority of CIN and cervical cancer. Vaccination is now recommended for girls and boys aged 11–13 in most national programmes.